The development of a dedicated leadership team was identified as a pivotal priority in the Cancer Center strategic planning process to ensure consultative, transparent and effective decision-making. This was accomplished in the last project period through a combination of new appointments, creation of new leadership positions in the Cancer Center and reconfiguration of existing roles for optimal impact on the cancer research agenda. As part of this reorganization. Dr. Rauscher was appointed as a the sole Deputy Director of the Cancer Center with a codified succession plan should the need arise to replace the current Director, and a second Deputy Director position that was previously filled by Dr. Herlyn was eliminated. Since the introduction of these changes, the senior leadership team has worked well together, guiding an extensive and transparent consultative process that involved every administrative, scientific and educational segment ofthe Cancer Center, and leading a stepwise but decisive implementation ofthe ensuing strategic directives. Together, the senior leaders prioritized changes in the scientific alignment of Programs and Shared Resources, directed an aggressive and successful faculty recruitment effort that brought to the Cancer Center seven new faculty members appointed at all academic ranks, refocused administrative functions and decision-making processes, identified opportunities for translational and patient-oriented cancer research and developed new initiatives to expand education and mentoring, including for underrepresented minorities. Overall, the senior leadership team has catalyzed the introduction of a productive culture of collaboration and scientific exchange that has transformed the Cancer Center in the last budget period, bringing about expansive gains in NCI and cancer-related funding, and significant increase in collaborative, joint publications across the three Cancer Center Programs. This positive trajectory will continue in the next budget period, when the leadership team will guide the largest faculty and facility expansion of the Cancer Center in forty years enabled by the opening of the new Wistar Research Tower

Public Health Relevance

The newly configured Cancer Center leadership team has successfully leveraged a lean, opportunity-driven administrative infrastructure to bring about expansive gains in cancer focus, collaborative science, joint funding and innovative education to fulfill the vision of the Cancer Center of conquering cancer through outstanding research, education and partnership.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Veglia, Filippo; Gabrilovich, Dmitry I (2017) Dendritic cells in cancer: the role revisited. Curr Opin Immunol 45:43-51
Tomescu, Costin; Tebas, Pablo; Montaner, Luis J (2017) IFN-? augments NK-mediated antibody-dependent cellular cytotoxicity (ADCC) of HIV-1 infected autologous CD4+ T cells regardless of MHC-I downregulation. AIDS :
Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417
Karpel-Massler, Georg; Ishida, Chiaki Tsuge; Bianchetti, Elena et al. (2017) Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res 77:3513-3526
Hoffman, Hunter; Rice, Cory; Skordalakes, Emmanuel (2017) Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes. J Biol Chem 292:4593-4601
Lu, Fang; Wiedmer, Andreas; Martin, Kayla A et al. (2017) Coordinate Regulation of TET2 and EBNA2 Control DNA Methylation State of Latent Epstein-Barr Virus. J Virol :
Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775
Lynch, Shannon M; Mitra, Nandita; Ravichandran, Krithika et al. (2017) Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiol Biomarkers Prev 26:553-560
Perales-Puchalt, Alfredo; Svoronos, Nikolaos; Rutkowski, Melanie R et al. (2017) Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clin Cancer Res 23:441-453
Bryant, Kelly G; Chae, Young Chan; Martinez, Rogelio L et al. (2017) A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy. Oncotarget 8:112184-112198

Showing the most recent 10 out of 685 publications